Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report

Mirza, Hassan; Harding, Duncan; Al‐Balushi, Naser

doi:10.18295/squmj.2018.18.02.014

Cited by 9 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After administration of the 2nd dose of PP, they increased again, and the drug was discontinued (14). Moreover, acute-onset delirium was seen after the second PP dose in an adolescent with schizophrenia (13). In our case, the use of the LAI form of haloperidol was not considered due to transaminitis reported in the literature (20)(21)(22).…”

Section: Discussionmentioning

confidence: 68%

“…Common adverse events with PP use were headache, vomiting, limb pain, and injection site pain (10). Patients with schizophrenia who developed acute persistent circulatory failure and extrapyramidal symptoms requiring vasopressors and mechanical ventilation with death resulting after receiving injections of PP have been reported in the literature (11,12), as have cases with delirium and liver enzyme elevation caused by PP (13,14). In this article, we present a case of high fever and high liver function tests (LFT) immediately after the first dose of PP.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of acute hepatotoxicity following the first dose of paliperidone palmitate: a case report

Erdoğan¹

2020

Dusunen Adam

View full text Add to dashboard Cite

Paliperidone palmitate (PP) is a long-acting antipsychotic administered intramuscularly once a month in the acute and maintenance treatments of schizophrenia. It has been reported to be successful especially in patients with poor oral drug compliance. The most common side effects are dizziness, sleepiness, anxiety, injection site reactions, and extrapyramidal system symptoms. The aim of this study is to draw attention to a rare side effect of PP and contribute to the literature by presenting a case of high fever and high liver function tests after application of the first dose.

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Introductionmentioning

confidence: 99%

Development of acute hepatotoxicity following the first dose of paliperidone palmitate: a case report

Erdoğan¹

2020

Dusunen Adam

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…Looking at the single case reports, two of them were based on the description of side effects [ 44 , 45 ]. Mirza et al [ 45 ] described a male adolescent inpatient with schizophrenia who developed a severe acute-onset delirium after the second dose of LAI paliperidone (first dose: 150 mg and second: 100 mg). The treatment was associated with an improvement of his symptoms, but 10 days after the second dose the patient needed an admission due to fluctuating levels of consciousness and additional symptoms of delirium.…”

Section: Resultsmentioning

confidence: 99%

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Background Long-acting injectable antipsychotics (LAIAs) are an efficacious and well-tolerated treatment in adults with schizophrenia spectrum disorders (SSD). However, there is less evidence for their use in children and adolescents. Objectives The aim of this systematic review was to summarize findings regarding the effectiveness and side effects of LAIA in children and adolescents with SSD. Methods Four databases (Web of Science, PubMed, MEDES, and Dialnet) were systematically searched for articles published between inception and 12 March, 2022, with the following inclusion criteria: (1) original articles or case reports; (2) providing data on efficacy/effectiveness or safety/tolerability of LAIA treatment in children and adolescents diagnosed with SSD (schizophrenia, schizoaffective disorder, schizophreniform disorder, non-affective psychotic disorder); (3) mean age of samples ≤ 18 years; and (4) written in English or Spanish. Exclusion criteria were review articles, clinical guides, expert consensus as well as posters or oral communication in conferences. The risk of bias was assessed using the ROBIS tool. Results From 847 articles found, 13 met the inclusion criteria. These included seven single case reports or case series, four retrospective chart reviews, a 24-week open-label trial, and one observational prospective study, covering a total of 119 adolescents (aged 12–17 years) with SSD. Almost all the articles described data on second-generation LAIA (53 patients on risperidone [once every other week], 33 on paliperidone palmitate [once monthly], 10 on aripiprazole [once monthly], and two on olanzapine pamoate [once monthly]). Twenty-one patients were reported to be only on first-generation LAIAs. Non-adherence was the main reason for starting an LAIA. In all of the studies, the use of LAIAs was associated with improvement in the patients’ symptoms. Conclusions There are few studies assessing the use of LAIAs in adolescents with SSD. Overall, these treatments have suggested good effectiveness and acceptable safety and tolerability. However, we found no studies examining their use in children aged < 12 years. The problems and benefits linked to this type of antipsychotic formulation in the child and adolescent population require further study, ideally with prospective, controlled designs. Supplementary Information The online version contains supplementary material available at 10.1007/s40272-023-00558-x.

show abstract

“…Of related interest, Mirza et al [16] have reported on an adolescent male with schizophrenia. Following poor compliance with oral medications, a 4-week regimen of paliperidone palmitate long-acting injections was initiated, with an initial positive response.…”

Section: Paliperidone Palmitate Long-acting Injectable In Cap Populationmentioning

confidence: 99%

Paliperidone Use in Child Psychiatry: Evidence or Diffidence?

2019

View full text Add to dashboard Cite

Background: Paliperidone is FDA-approved for schizophrenia aged 12–17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. Methods: EMBASE, Ovid MEDLINE, PubMed, Scopus, Web of Science, and Cochrane Database of Systemic Reviews were searched for all relevant studies of using paliperidone in child psychiatry up to date of February 2019. Results: Sound evidence base supports its use in early-onset schizophrenia, juvenile bipolar, and autism spectrum disorder. A modicum of evidence supports its use in Tourette syndrome and as adjuventia in attention-deficit/hyperactivity disorder (ADHD). Conclusion: Paliperidone has some dynamic and kinetic superiority to the parent drug risperidone. Nonetheless, larger rigorous studies would define the real place of the atypical antipsychotic paliperidone in child and adolescent psychiatry. Until then, risperidone with its long track record in CAP population would remain a first option though.

show abstract

Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report

Cited by 9 publications

References 12 publications

Development of acute hepatotoxicity following the first dose of paliperidone palmitate: a case report

Development of acute hepatotoxicity following the first dose of paliperidone palmitate: a case report

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review

Paliperidone Use in Child Psychiatry: Evidence or Diffidence?

Contact Info

Product

Resources

About